iShares Nasdaq Biotechnology (IBB) Spikes on Biogen Headlines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
August 2, 2016 3:41 PM EDTBiogen (NASDAQ: BIIB) could be worth $375-$475/share in a takeover RBC Capital's Michael Yee said following reports from the WSJ the company has attracted takeover... More
